0000899243-20-002488.txt : 20200131 0000899243-20-002488.hdr.sgml : 20200131 20200131185034 ACCESSION NUMBER: 0000899243-20-002488 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200131 FILED AS OF DATE: 20200131 DATE AS OF CHANGE: 20200131 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MUEHL DANIEL W CENTRAL INDEX KEY: 0001283569 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35347 FILM NUMBER: 20566505 MAIL ADDRESS: STREET 1: 5 BILLERICA PARK STREET 2: 101 BILLERICA AVE CITY: NORTH BILLERCA STATE: MA ZIP: 01862 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Clovis Oncology, Inc. CENTRAL INDEX KEY: 0001466301 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900475355 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (303) 625-5000 MAIL ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-01-31 0 0001466301 Clovis Oncology, Inc. CLVS 0001283569 MUEHL DANIEL W C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY, SUITE 100 BOULDER CO 80301 0 1 0 0 See Remarks Restricted Stock Units 2020-01-31 4 A 0 74000 0.00 A Common Stock 74000 74000 D Each Restricted Stock Unit represents the right to receive one share of Common Stock. The Restricted Stock Units shall vest as to 25% of the units on February 1, 2021, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date. Senior Vice President of Finance, Principal Financial Officer and Principal Accounting Officer /s/ Daniel W. Muehl 2020-01-31